Annual FCF
$10.16 B
+$1.07 B+11.80%
31 December 2023
Summary:
Novo Nordisk A/S annual free cash flow is currently $10.16 billion, with the most recent change of +$1.07 billion (+11.80%) on 31 December 2023. During the last 3 years, it has risen by +$5.59 billion (+122.10%). NVO annual FCF is now at all-time high.NVO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$4.75 B
-$623.64 M-11.61%
30 September 2024
Summary:
Novo Nordisk A/S quarterly free cash flow is currently $4.75 billion, with the most recent change of -$623.64 million (-11.61%) on 30 September 2024. Over the past year, it has increased by +$323.01 million (+7.30%). NVO quarterly FCF is now -11.61% below its all-time high of $5.37 billion, reached on 30 June 2024.NVO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$9.83 B
+$323.01 M+3.40%
30 September 2024
Summary:
Novo Nordisk A/S TTM free cash flow is currently $9.83 billion, with the most recent change of +$323.01 million (+3.40%) on 30 September 2024. Over the past year, it has dropped by -$1.94 billion (-16.46%). NVO TTM FCF is now -16.46% below its all-time high of $11.76 billion, reached on 30 September 2023.NVO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVO Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +11.8% | +7.3% | -16.5% |
| 3 y3 years | +122.1% | +57.0% | +56.5% |
| 5 y5 years | +99.3% | +126.8% | +76.0% |
NVO Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +122.1% | -11.6% | +546.0% | -16.5% | +56.5% |
| 5 y | 5 years | at high | +122.1% | -11.6% | +324.4% | -16.5% | +114.8% |
| alltime | all time | at high | +9909.3% | -11.6% | +324.4% | -16.5% | +6037.7% |
Novo Nordisk A/S Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.75 B(-11.6%) | $9.83 B(+3.4%) |
| June 2024 | - | $5.37 B(+595.2%) | $9.51 B(+29.7%) |
| Mar 2024 | - | $772.71 M(-172.6%) | $7.33 B(-27.9%) |
| Dec 2023 | $10.16 B(+11.8%) | -$1.06 B(-124.1%) | $10.16 B(-13.6%) |
| Sept 2023 | - | $4.43 B(+38.4%) | $11.76 B(+21.1%) |
| June 2023 | - | $3.20 B(-11.4%) | $9.71 B(+3.2%) |
| Mar 2023 | - | $3.61 B(+574.7%) | $9.41 B(+3.5%) |
| Dec 2022 | $9.09 B(+20.0%) | $534.67 M(-77.5%) | $9.09 B(+17.5%) |
| Sept 2022 | - | $2.37 B(-18.0%) | $7.74 B(-7.8%) |
| June 2022 | - | $2.89 B(-12.0%) | $8.39 B(-9.6%) |
| Mar 2022 | - | $3.29 B(-502.4%) | $9.28 B(+22.5%) |
| Dec 2021 | $7.58 B(+65.5%) | -$817.54 M(-127.0%) | $7.58 B(+20.7%) |
| Sept 2021 | - | $3.03 B(-20.1%) | $6.28 B(+17.6%) |
| June 2021 | - | $3.79 B(+139.5%) | $5.34 B(+8.2%) |
| Mar 2021 | - | $1.58 B(-174.7%) | $4.93 B(+7.8%) |
| Dec 2020 | $4.58 B(-14.1%) | -$2.12 B(-201.4%) | $4.58 B(-35.1%) |
| Sept 2020 | - | $2.09 B(-38.3%) | $7.05 B(-0.1%) |
| June 2020 | - | $3.38 B(+176.3%) | $7.06 B(+28.1%) |
| Mar 2020 | - | $1.22 B(+238.1%) | $5.51 B(+3.4%) |
| Dec 2019 | $5.33 B(+4.5%) | $361.95 M(-82.7%) | $5.33 B(-4.5%) |
| Sept 2019 | - | $2.09 B(+14.2%) | $5.58 B(+17.3%) |
| June 2019 | - | $1.83 B(+75.7%) | $4.76 B(-5.0%) |
| Mar 2019 | - | $1.04 B(+69.7%) | $5.01 B(-1.7%) |
| Dec 2018 | $5.10 B(+3.1%) | $614.42 M(-51.7%) | $5.10 B(+7.6%) |
| Sept 2018 | - | $1.27 B(-39.0%) | $4.74 B(-12.0%) |
| June 2018 | - | $2.08 B(+84.3%) | $5.39 B(+17.2%) |
| Mar 2018 | - | $1.13 B(+346.4%) | $4.59 B(-7.2%) |
| Dec 2017 | $4.95 B(-16.8%) | $253.41 M(-86.8%) | $4.95 B(-16.1%) |
| Sept 2017 | - | $1.92 B(+48.3%) | $5.90 B(+1.1%) |
| June 2017 | - | $1.29 B(-13.2%) | $5.84 B(-10.3%) |
| Mar 2017 | - | $1.49 B(+23.4%) | $6.50 B(+9.3%) |
| Dec 2016 | $5.95 B(+25.5%) | $1.21 B(-34.9%) | $5.95 B(+3.1%) |
| Sept 2016 | - | $1.85 B(-5.5%) | $5.78 B(+4.2%) |
| June 2016 | - | $1.96 B(+109.2%) | $5.54 B(+7.1%) |
| Mar 2016 | - | $936.48 M(-9.0%) | $5.18 B(+9.2%) |
| Dec 2015 | $4.74 B(-2.9%) | $1.03 B(-36.5%) | $4.74 B(-0.2%) |
| Sept 2015 | - | $1.62 B(+1.6%) | $4.75 B(-5.8%) |
| June 2015 | - | $1.59 B(+217.9%) | $5.05 B(+5.5%) |
| Mar 2015 | - | $501.18 M(-51.8%) | $4.78 B(-2.0%) |
| Dec 2014 | $4.88 B(+23.0%) | $1.04 B(-45.7%) | $4.88 B(+4.9%) |
| Sept 2014 | - | $1.91 B(+43.9%) | $4.66 B(+25.8%) |
| June 2014 | - | $1.33 B(+121.8%) | $3.70 B(+6.4%) |
| Mar 2014 | - | $599.92 M(-26.0%) | $3.48 B(-12.4%) |
| Dec 2013 | $3.97 B(+23.7%) | $810.97 M(-15.4%) | $3.97 B(+19.9%) |
| Sept 2013 | - | $958.68 M(-13.5%) | $3.31 B(-4.3%) |
| June 2013 | - | $1.11 B(+1.5%) | $3.46 B(+1.3%) |
| Mar 2013 | - | $1.09 B(+619.2%) | $3.42 B(+6.4%) |
| Dec 2012 | $3.21 B | $151.91 M(-86.3%) | $3.21 B(-8.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $1.11 B(+4.1%) | $3.52 B(-5.5%) |
| June 2012 | - | $1.06 B(+20.1%) | $3.72 B(+8.4%) |
| Mar 2012 | - | $886.23 M(+93.4%) | $3.43 B(+1.8%) |
| Dec 2011 | $3.37 B(+19.9%) | $458.26 M(-65.1%) | $3.37 B(-6.3%) |
| Sept 2011 | - | $1.31 B(+69.2%) | $3.60 B(+10.9%) |
| June 2011 | - | $775.20 M(-6.1%) | $3.24 B(+7.9%) |
| Mar 2011 | - | $825.61 M(+20.7%) | $3.00 B(+6.8%) |
| Dec 2010 | $2.81 B(+22.0%) | $684.22 M(-28.5%) | $2.81 B(+11.2%) |
| Sept 2010 | - | $956.43 M(+78.1%) | $2.53 B(+3.7%) |
| June 2010 | - | $536.90 M(-15.3%) | $2.44 B(+5.7%) |
| Mar 2010 | - | $633.51 M(+58.2%) | $2.31 B(+0.1%) |
| Dec 2009 | $2.30 B(+7.8%) | $400.55 M(-53.8%) | $2.30 B(-1.8%) |
| Sept 2009 | - | $866.63 M(+113.8%) | $2.35 B(+12.7%) |
| June 2009 | - | $405.26 M(-35.9%) | $2.08 B(-5.7%) |
| Mar 2009 | - | $631.92 M(+42.7%) | $2.21 B(+3.3%) |
| Dec 2008 | $2.14 B(+53.6%) | $442.86 M(-26.4%) | $2.14 B(+6.1%) |
| Sept 2008 | - | $602.09 M(+13.3%) | $2.01 B(+3.1%) |
| June 2008 | - | $531.28 M(-5.4%) | $1.95 B(+23.3%) |
| Mar 2008 | - | $561.83 M(+76.1%) | $1.58 B(+13.9%) |
| Dec 2007 | $1.39 B(+86.8%) | $319.12 M(-41.1%) | $1.39 B(+48.2%) |
| Sept 2007 | - | $542.22 M(+235.6%) | $938.86 M(+9.1%) |
| June 2007 | - | $161.57 M(-56.2%) | $860.33 M(-1.4%) |
| Mar 2007 | - | $368.94 M(-375.6%) | $872.96 M(+17.2%) |
| Dec 2006 | $745.15 M(-7.1%) | -$133.87 M(-128.9%) | $745.15 M(-29.7%) |
| Sept 2006 | - | $463.69 M(+166.2%) | $1.06 B(+20.2%) |
| June 2006 | - | $174.20 M(-27.8%) | $881.55 M(-5.6%) |
| Mar 2006 | - | $241.13 M(+33.8%) | $934.06 M(+16.4%) |
| Dec 2005 | $802.34 M(+7.0%) | $180.28 M(-37.0%) | $802.34 M(+3.7%) |
| Sept 2005 | - | $285.93 M(+26.1%) | $773.45 M(+2.0%) |
| June 2005 | - | $226.71 M(+107.2%) | $758.34 M(+8.5%) |
| Mar 2005 | - | $109.41 M(-27.7%) | $699.17 M(-6.8%) |
| Dec 2004 | $749.89 M(+34.4%) | $151.39 M(-44.1%) | $749.89 M(+25.3%) |
| Sept 2004 | - | $270.83 M(+61.7%) | $598.50 M(+82.7%) |
| June 2004 | - | $167.54 M(+4.6%) | $327.67 M(+104.6%) |
| Mar 2004 | - | $160.13 M | $160.13 M |
| Dec 2003 | $558.07 M(+373.0%) | - | - |
| Dec 2002 | $117.99 M(+161.1%) | - | - |
| Dec 2001 | $45.18 M(-87.4%) | - | - |
| Dec 2000 | $358.91 M(+70.1%) | - | - |
| Dec 1999 | $210.99 M(+107.1%) | - | - |
| Dec 1998 | $101.86 M(+59.2%) | - | - |
| Dec 1997 | $63.97 M(-395.0%) | - | - |
| Dec 1996 | -$21.68 M(-113.1%) | - | - |
| Dec 1995 | $166.11 M(+13.9%) | - | - |
| Dec 1994 | $145.86 M(-293.9%) | - | - |
| Dec 1993 | -$75.24 M(-27.4%) | - | - |
| Dec 1992 | -$103.62 M(+303.6%) | - | - |
| Dec 1991 | -$25.68 M(-147.6%) | - | - |
| Dec 1990 | $53.89 M | - | - |
FAQ
- What is Novo Nordisk A/S annual free cash flow?
- What is the all time high annual FCF for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual FCF year-on-year change?
- What is Novo Nordisk A/S quarterly free cash flow?
- What is the all time high quarterly FCF for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly FCF year-on-year change?
- What is Novo Nordisk A/S TTM free cash flow?
- What is the all time high TTM FCF for Novo Nordisk A/S?
- What is Novo Nordisk A/S TTM FCF year-on-year change?
What is Novo Nordisk A/S annual free cash flow?
The current annual FCF of NVO is $10.16 B
What is the all time high annual FCF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual free cash flow is $10.16 B
What is Novo Nordisk A/S annual FCF year-on-year change?
Over the past year, NVO annual free cash flow has changed by +$1.07 B (+11.80%)
What is Novo Nordisk A/S quarterly free cash flow?
The current quarterly FCF of NVO is $4.75 B
What is the all time high quarterly FCF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly free cash flow is $5.37 B
What is Novo Nordisk A/S quarterly FCF year-on-year change?
Over the past year, NVO quarterly free cash flow has changed by +$323.01 M (+7.30%)
What is Novo Nordisk A/S TTM free cash flow?
The current TTM FCF of NVO is $9.83 B
What is the all time high TTM FCF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high TTM free cash flow is $11.76 B
What is Novo Nordisk A/S TTM FCF year-on-year change?
Over the past year, NVO TTM free cash flow has changed by -$1.94 B (-16.46%)